Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Novavax, Canada finalize purchase agreement on COVID vaccine » 17:24
01/22/21
01/22
17:24
01/22/21
17:24
NVAX

Novavax

$126.99 /

+4.78 (+3.91%)

Novavax announced that it…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NVAX Novavax
$126.99 /

+4.78 (+3.91%)

NVAX Novavax
$126.99 /

+4.78 (+3.91%)

12/29/20 B. Riley Securities
Novavax selloff yesterday brings 'compelling' opportunity, says B. Riley
12/28/20 JPMorgan
JPMorgan sees data from Novavax vaccine trial in U.S. in March/April
12/14/20 Jefferies
Novavax initiated with a Buy at Jefferies
12/07/20 B. Riley Securities
Arcturus Therapeutics price target raised to $111 from $64 at B. Riley
NVAX Novavax
$126.99 /

+4.78 (+3.91%)

NVAX Novavax
$126.99 /

+4.78 (+3.91%)

NVAX Novavax
$126.99 /

+4.78 (+3.91%)

NVAX Novavax
$126.99 /

+4.78 (+3.91%)

Periodicals
AstraZeneca to slash EU COVID-19 vaccine deliveries by 60% in Q1, Reuters says » 15:25
01/22/21
01/22
15:25
01/22/21
15:25
AZN

AstraZeneca

$53.21 /

+0.68 (+1.29%)

AstraZeneca has informed…

AstraZeneca has informed European Union officials that it would reduce deliveries of its coronavirus vaccine to the bloc by 60% to 31M doses in the first quarter of 2021 due to production issues, Reuters' Francesco Guarascio reports, citing a senior official. The company was forecast to deliver to the 27 EU countries roughly 80M shots by the end of March, the author notes, citing the official who was involved in the talks. Reference Link

ShowHide Related Items >><<
AZN AstraZeneca
$53.21 /

+0.68 (+1.29%)

AZN AstraZeneca
$53.21 /

+0.68 (+1.29%)

15:00 Today Barclays
AstraZeneca price target lowered to 9,000 GBp from 9,300 GBp at Barclays
01/19/21 BTIG
Adaptive Biotechnologies price target raised to $74 from $66 at BTIG
01/15/21 Berenberg
AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg
01/15/21
Fly Intel: Top five analyst initiations
AZN AstraZeneca
$53.21 /

+0.68 (+1.29%)

AZN AstraZeneca
$53.21 /

+0.68 (+1.29%)

AZN AstraZeneca
$53.21 /

+0.68 (+1.29%)

AZN AstraZeneca
$53.21 /

+0.68 (+1.29%)

Recommendations
AstraZeneca price target lowered to 9,000 GBp from 9,300 GBp at Barclays » 15:00
01/22/21
01/22
15:00
01/22/21
15:00
AZN

AstraZeneca

$53.30 /

+0.77 (+1.47%)

Barclays analyst Emmanuel…

Barclays analyst Emmanuel Papadakis lowered the firm's price target on AstraZeneca to 9,000 GBp from 9,300 GBp and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
AZN AstraZeneca
$53.30 /

+0.77 (+1.47%)

AZN AstraZeneca
$53.30 /

+0.77 (+1.47%)

01/19/21 BTIG
Adaptive Biotechnologies price target raised to $74 from $66 at BTIG
01/15/21 Berenberg
AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg
01/15/21
Fly Intel: Top five analyst initiations
01/15/21 Deutsche Bank
AstraZeneca initiated with a Buy at Deutsche Bank
AZN AstraZeneca
$53.30 /

+0.77 (+1.47%)

AZN AstraZeneca
$53.30 /

+0.77 (+1.47%)

AZN AstraZeneca
$53.30 /

+0.77 (+1.47%)

AZN AstraZeneca
$53.30 /

+0.77 (+1.47%)

Periodicals
EU to see delay of AstraZeneca COVID vaccine delivery, FT reports » 11:53
01/22/21
01/22
11:53
01/22/21
11:53
AZN

AstraZeneca

$53.07 /

+0.54 (+1.03%)

The European Union will…

The European Union will experience a delay in the delivery of COVID-19 vaccines made by AstraZeneca in partnership with Oxford, the Financial Times reports. The company said that initial volumes of the vaccine will be "lower than originally anticipated," the report says. Reference Link

ShowHide Related Items >><<
AZN AstraZeneca
$53.07 /

+0.54 (+1.03%)

AZN AstraZeneca
$53.07 /

+0.54 (+1.03%)

01/19/21 BTIG
Adaptive Biotechnologies price target raised to $74 from $66 at BTIG
01/15/21 Berenberg
AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg
01/15/21
Fly Intel: Top five analyst initiations
01/15/21 Deutsche Bank
AstraZeneca initiated with a Buy at Deutsche Bank
AZN AstraZeneca
$53.07 /

+0.54 (+1.03%)

AZN AstraZeneca
$53.07 /

+0.54 (+1.03%)

AZN AstraZeneca
$53.07 /

+0.54 (+1.03%)

AZN AstraZeneca
$53.07 /

+0.54 (+1.03%)

Periodicals
AstraZeneca informs EU Commission of vaccine delivery issues, Bild says » 10:38
01/22/21
01/22
10:38
01/22/21
10:38
AZN

AstraZeneca

$53.02 /

+0.49 (+0.93%)

A translation of a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AZN AstraZeneca
$53.02 /

+0.49 (+0.93%)

AZN AstraZeneca
$53.02 /

+0.49 (+0.93%)

01/19/21 BTIG
Adaptive Biotechnologies price target raised to $74 from $66 at BTIG
01/15/21 Berenberg
AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg
01/15/21
Fly Intel: Top five analyst initiations
01/15/21 Deutsche Bank
AstraZeneca initiated with a Buy at Deutsche Bank
AZN AstraZeneca
$53.02 /

+0.49 (+0.93%)

AZN AstraZeneca
$53.02 /

+0.49 (+0.93%)

AZN AstraZeneca
$53.02 /

+0.49 (+0.93%)

AZN AstraZeneca
$53.02 /

+0.49 (+0.93%)

Options
Marathon Patent Group call volume above normal and directionally bullish » 10:25
01/22/21
01/22
10:25
01/22/21
10:25
MARA

Marathon Patent Group

$19.49 /

+1.925 (+10.96%)

Bullish option flow…

Bullish option flow detected in Marathon Patent Group with 41,912 calls trading, 1.6x expected, and implied vol increasing almost 8 points to 201.65%. 1/22 weekly 19.5 calls and 1/22 weekly 20 calls are the most active options, with total volume in those strikes near 6,300 contracts. The Put/Call Ratio is 0.27. Earnings are expected on March 23rd.

ShowHide Related Items >><<
MARA Marathon Patent Group
$19.49 /

+1.925 (+10.96%)

MARA Marathon Patent Group
$19.49 /

+1.925 (+10.96%)

11/23/20 H.C. Wainwright
Marathon Patent Group initiated with a Buy at H.C. Wainwright
MARA Marathon Patent Group
$19.49 /

+1.925 (+10.96%)

  • 24
    Jul
MARA Marathon Patent Group
$19.49 /

+1.925 (+10.96%)

MARA Marathon Patent Group
$19.49 /

+1.925 (+10.96%)

On The Fly
The Intersection: Crypto and Wall Street This Week » 09:39
01/22/21
01/22
09:39
01/22/21
09:39
BTC

Bitcoin

$0.00 /

+ (+0.00%)

, BITCOIN

Bitcoin

$0.00 /

+ (+0.00%)

, BLK

BlackRock

$742.10 /

+0.41 (+0.06%)

, COIN

Coinbase

$0.00 /

+ (+0.00%)

, CLSK

CleanSpark

$25.20 /

-3.08 (-10.89%)

, RIOT

Riot Blockchain

$19.34 /

-2.925 (-13.14%)

, AMD

AMD

$91.52 /

+2.76 (+3.11%)

, NVDA

Nvidia

$554.67 /

+19.64 (+3.67%)

, OSTK

Overstock.com

$63.73 /

+2.78 (+4.56%)

, IDEX

Ideanomics

$3.17 /

-0.09 (-2.76%)

, TEUM

Pareteum

$0.27 /

+ (+0.00%)

, SRAX

Srax

$3.08 /

-0.1 (-3.14%)

As bitcoin, ethereum and…

ShowHide Related Items >><<
TEUM Pareteum
$0.27 /

+ (+0.00%)

SRAX Srax
$3.08 /

-0.1 (-3.14%)

RIOT Riot Blockchain
$19.34 /

-2.925 (-13.14%)

OSTK Overstock.com
$63.73 /

+2.78 (+4.56%)

NVDA Nvidia
$554.67 /

+19.64 (+3.67%)

IDEX Ideanomics
$3.17 /

-0.09 (-2.76%)

CLSK CleanSpark
$25.20 /

-3.08 (-10.89%)

BTC Bitcoin
$0.00 /

+ (+0.00%)

BLK BlackRock
$742.10 /

+0.41 (+0.06%)

BITCOIN Bitcoin
$0.00 /

+ (+0.00%)

AMD AMD
$91.52 /

+2.76 (+3.11%)

BTC Bitcoin
$0.00 /

+ (+0.00%)

01/13/21 Standpoint Research
Bitcoin could hit $112,000 this year, says Standpoint Research
01/23/20 Morgan Stanley
PayPal acceptance gap widens against Amazon, Bitcoin, says Morgan Stanley
BITCOIN Bitcoin
$0.00 /

+ (+0.00%)

BLK BlackRock
$742.10 /

+0.41 (+0.06%)

01/19/21 RBC Capital
PNC Financial price target raised to $161 from $135 at RBC Capital
01/15/21 BMO Capital
BlackRock price target raised to $715 from $709 at BMO Capital
01/15/21 Deutsche Bank
BlackRock price target raised to $838 from $835 at Deutsche Bank
01/15/21 Barclays
BlackRock price target raised to $850 from $800 at Barclays
COIN Coinbase
$0.00 /

+ (+0.00%)

CLSK CleanSpark
$25.20 /

-3.08 (-10.89%)

12/11/20 H.C. Wainwright
CleanSpark price target raised to $24 from $18 at H.C. Wainwright
RIOT Riot Blockchain
$19.34 /

-2.925 (-13.14%)

11/23/20 H.C. Wainwright
Riot Blockchain price target raised to $7.50 from $3.50 at H.C. Wainwright
AMD AMD
$91.52 /

+2.76 (+3.11%)

08:59 Today Truist
Intel price target raised to $64 from $60 at Truist
01/14/21 Cowen
AMD price target raised to $110 from $100 at Cowen
01/14/21 BMO Capital
Intel upgraded to Outperform from Market Perform at BMO Capital
01/14/21 BMO Capital
AMD downgraded to Underperform from Market Perform at BMO Capital
NVDA Nvidia
$554.67 /

+19.64 (+3.67%)

01/15/21 Truist
Nvidia price target raised to $672 from $643 at Truist
01/15/21 Susquehanna
Nvidia price target raised to $625 from $610 at Susquehanna
01/12/21 Wells Fargo
Nvidia very-well positioned as gaming momentum continues, says Wells Fargo
01/11/21 JPMorgan
NIO Inc. price target raised to $75 from $50 at JPMorgan
OSTK Overstock.com
$63.73 /

+2.78 (+4.56%)

11/02/20 Wedbush
Overstock.com price target raised to $98 from $92 at Wedbush
11/02/20 Wedbush
Overstock.com removed from Best Ideas List at Wedbush
10/30/20 Wedbush
Overstock.com price target raised to $98 from $92 at Wedbush
10/30/20 Piper Sandler
Overstock.com weakness a buying opportunity, says Piper Sandler
IDEX Ideanomics
$3.17 /

-0.09 (-2.76%)

TEUM Pareteum
$0.27 /

+ (+0.00%)

SRAX Srax
$3.08 /

-0.1 (-3.14%)

07/06/20
Fly Intel: Top five analyst initiations
07/06/20 B. Riley Securities
B. Riley FBR starts Srax at Buy on 'rapid adoption' of Sequire
07/06/20 B. Riley Securities
Srax initiated with a Buy at B. Riley FBR
OSTK Overstock.com
$63.73 /

+2.78 (+4.56%)

NVDA Nvidia
$554.67 /

+19.64 (+3.67%)

IDEX Ideanomics
$3.17 /

-0.09 (-2.76%)

CLSK CleanSpark
$25.20 /

-3.08 (-10.89%)

BTC Bitcoin
$0.00 /

+ (+0.00%)

BLK BlackRock
$742.10 /

+0.41 (+0.06%)

AMD AMD
$91.52 /

+2.76 (+3.11%)

  • 07
    Oct
  • 12
    Aug
  • 13
    May
OSTK Overstock.com
$63.73 /

+2.78 (+4.56%)

NVDA Nvidia
$554.67 /

+19.64 (+3.67%)

CLSK CleanSpark
$25.20 /

-3.08 (-10.89%)

BTC Bitcoin
$0.00 /

+ (+0.00%)

BLK BlackRock
$742.10 /

+0.41 (+0.06%)

BITCOIN Bitcoin
$0.00 /

+ (+0.00%)

AMD AMD
$91.52 /

+2.76 (+3.11%)

RIOT Riot Blockchain
$19.34 /

-2.925 (-13.14%)

OSTK Overstock.com
$63.73 /

+2.78 (+4.56%)

NVDA Nvidia
$554.67 /

+19.64 (+3.67%)

COIN Coinbase
$0.00 /

+ (+0.00%)

CLSK CleanSpark
$25.20 /

-3.08 (-10.89%)

BTC Bitcoin
$0.00 /

+ (+0.00%)

BLK BlackRock
$742.10 /

+0.41 (+0.06%)

AMD AMD
$91.52 /

+2.76 (+3.11%)

RIOT Riot Blockchain
$19.34 /

-2.925 (-13.14%)

OSTK Overstock.com
$63.73 /

+2.78 (+4.56%)

NVDA Nvidia
$554.67 /

+19.64 (+3.67%)

IDEX Ideanomics
$3.17 /

-0.09 (-2.76%)

CLSK CleanSpark
$25.20 /

-3.08 (-10.89%)

BLK BlackRock
$742.10 /

+0.41 (+0.06%)

AMD AMD
$91.52 /

+2.76 (+3.11%)

Downgrade
Sage Therapeutics cut to Market Perform at BMO Capital on valuation » 06:56
01/22/21
01/22
06:56
01/22/21
06:56
SAGE

Sage Therapeutics

$92.45 /

+1.19 (+1.30%)

As previously reported,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SAGE Sage Therapeutics
$92.45 /

+1.19 (+1.30%)

SAGE Sage Therapeutics
$92.45 /

+1.19 (+1.30%)

05:08 Today BMO Capital
Sage Therapeutics downgraded to Market Perform from Outperform at BMO Capital
01/19/21 Wedbush
Sage Therapeutics price target raised to $98 from $83 at Wedbush
01/04/21
Sage Therapeutics downgraded to Sector Perform at RBC Capital on valuation
01/04/21 Guggenheim
Sage Therapeutics upgraded to Buy from Neutral at Guggenheim
SAGE Sage Therapeutics
$92.45 /

+1.19 (+1.30%)

SAGE Sage Therapeutics
$92.45 /

+1.19 (+1.30%)

Downgrade
Sage Therapeutics downgraded to Market Perform from Outperform at BMO Capital » 05:08
01/22/21
01/22
05:08
01/22/21
05:08
SAGE

Sage Therapeutics

$92.45 /

+1.19 (+1.30%)

BMO Capital analyst Gary…

BMO Capital analyst Gary Nachman downgraded Sage Therapeutics to Market Perform from Outperform with a $95 price target.

ShowHide Related Items >><<
SAGE Sage Therapeutics
$92.45 /

+1.19 (+1.30%)

SAGE Sage Therapeutics
$92.45 /

+1.19 (+1.30%)

01/19/21 Wedbush
Sage Therapeutics price target raised to $98 from $83 at Wedbush
01/04/21
Sage Therapeutics downgraded to Sector Perform at RBC Capital on valuation
01/04/21 Guggenheim
Sage Therapeutics upgraded to Buy from Neutral at Guggenheim
01/04/21 RBC Capital
Sage Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
SAGE Sage Therapeutics
$92.45 /

+1.19 (+1.30%)

SAGE Sage Therapeutics
$92.45 /

+1.19 (+1.30%)

Yesterday
Hot Stocks
Moderna announces 1st participant dosed in Japan study of Moderna COVID vaccine » 09:05
01/21/21
01/21
09:05
01/21/21
09:05
MRNA

Moderna

$125.14 /

+0.12 (+0.10%)

, TAK

Takeda Pharmaceutical

$17.59 /

+0.145 (+0.83%)

Moderna (MRNA) announced…

Moderna (MRNA) announced that the first participant has been dosed in the Phase 1/2 study of Moderna's vaccine candidate against COVID-19, mRNA-1273 or TAK-919, in Japan, led by Takeda Pharmaceutical (TAK). TAK-919 is Takeda's development code for Moderna's COVID-19 vaccine candidate. "We are pleased that this Phase 1/2 study of our COVID-19 vaccine in healthy adults in Japan has begun. This is the first clinical trial of a Moderna product in Japan and we thank Takeda for partnering with us to potentially protect the Japanese population from COVID-19 with a vaccine," said Stephane Bancel, Chief Executive Officer of Moderna. This placebo-controlled Phase 1/2 study will evaluate the safety and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart. Takeda intends to enroll 200 participants aged 20 years and above in Japan. Each participant will be assigned to receive a placebo or a 100 undefined dose at both vaccinations. Participants will be followed through 12 months after the second vaccination. The ClinicalTrials.gov identifier is NCT04677660. Takeda and Moderna previously announced that Takeda will import and distribute 50 million doses of Moderna's COVID-19 vaccine candidate starting in the first half of 2021, pending licensure in Japan.

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$17.59 /

+0.145 (+0.83%)

MRNA Moderna
$125.14 /

+0.12 (+0.10%)

MRNA Moderna
$125.14 /

+0.12 (+0.10%)

01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/06/21 Piper Sandler
Moderna price target raised to $170 after EU vaccine approval at Piper Sandler
01/04/21 Piper Sandler
Moderna shares warrant 'fresh look' after 41% pullback, says Piper Sandler
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
TAK Takeda Pharmaceutical
$17.59 /

+0.145 (+0.83%)

12/29/20 Needham
Needham names Phathom Pharmaceuticals Top Pick for 2021
12/15/20 Needham
Phathom Pharmaceuticals price target raised to $55 from $45 at Needham
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
MRNA Moderna
$125.14 /

+0.12 (+0.10%)

  • 19
    May
  • 12
    Feb
TAK Takeda Pharmaceutical
$17.59 /

+0.145 (+0.83%)

MRNA Moderna
$125.14 /

+0.12 (+0.10%)

TAK Takeda Pharmaceutical
$17.59 /

+0.145 (+0.83%)

MRNA Moderna
$125.14 /

+0.12 (+0.10%)

MRNA Moderna
$125.14 /

+0.12 (+0.10%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.